Piramal Pharma Receives Improved ESG Rating for FY 2024-25
Piramal Pharma Ltd announced that it received an Environment, Social, and Governance (ESG) Rating of '64' for the fiscal year 2024-25. This rating was assigned by NSE Sustainability Ratings and Analytics Limited (NSE Sustainability).The rating marks an improvement from the previous score of 61, reflecting the company's continued dedication to responsible operations and sustainability efforts.
The ESG Rating was based on data made available by Piramal Pharma Ltd in the public domain for that year. NSE Sustainability voluntarily prepared the report considering the ESG factors reported by the Company.
PPLPHARMA Stock Price Movement
At the close of trade today, shares of Piramal Pharma Limited rallied by 1.16% to trade at ₹143.83. The stock managed an intraday sweep between ₹137.3 and ₹145 on robust trading activity with over 2.79 million shares moving through the system.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.